STOCK TITAN

MEDIPHARM LABS CORP - MEDIF STOCK NEWS

Welcome to our dedicated page for MEDIPHARM LABS news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on MEDIPHARM LABS stock.

MediPharm Labs Corp (MEDIF) is a pharmaceutical company specializing in precision-based cannabinoids. With GMP certification from ANVISA, FDA, EU, and TGA, MediPharm leads in pharmaceutical cannabinoids. They manufacture authorized medical cannabis products in compliance with strict regulations, including products for the Brazilian market under Resolution 327/19. By acquiring VIVO Cannabis, MediPharm expanded its reach to Canada, Australia, and Germany, offering a full suite of cannabis products to domestic and international medical markets.

Rhea-AI Summary

MediPharm Labs Corp. (OTCQX: MEDIF) will release its first quarter financial results for the period ended March 31, 2021, before the market opens on May 17, 2021. An audio conference call will follow at 8:30 a.m. ET to discuss the results and outlook. The company specializes in producing pharmaceutical-quality cannabis products and is recognized for its advanced extraction techniques. MediPharm has commercialized its extraction facility in Australia and focuses on research-driven product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
conferences earnings
-
Rhea-AI Summary

MediPharm Labs Corp. (OTCQX: MEDIF) has signed a two-year agreement with MT Pharma to supply GMP certified cannabis oil for patient distribution. This agreement underscores MediPharm's growth potential in the international pharmaceutical cannabis market, as they expand their customer base across 9 countries. The company has recently completed exports to Germany, Peru, and Australia, and anticipates further international expansion in 2023, including Brazil and New Zealand. MediPharm Labs emphasizes its commitment to high-quality, pharmaceutical-grade products in a rapidly evolving cannabis marketplace.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
-
Rhea-AI Summary

IM Cannabis Corp. (CSE:IMCC)(NASDAQ:IMCC) announced a two-year supply agreement with MediPharm Labs to enhance its product offerings in Germany. This agreement allows IMC's subsidiary, Adjupharm, to introduce a new range of IMC-branded extracts, including high THC and balanced THC/CBD oils. The products are expected to launch in the second half of 2021, targeting the growing demand for medical cannabis. The partnership aims to strengthen IMC's position as a leader in the expanding German extracts market while fulfilling patient needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
none
Rhea-AI Summary

MediPharm Labs has successfully exported its high THC medical cannabis to Peru, marking its first shipment to a Latin American country. This step follows successful exports to Australia and Germany. The shipment, handled by Cann Farm Peru S.A.C., aims to provide patients with consistent access to quality THC products, which are essential for addressing varied therapeutic needs.

Peru's medical cannabis market is rapidly advancing, offering significant growth potential for MediPharm Labs as it expands operations into Latin America.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
-
Rhea-AI Summary

MediPharm Labs has successfully exported its first shipment of medical cannabis oil products to Germany, approved by the Australian Therapeutic Goods Administration (TGA). This achievement marks a significant milestone for both the company and Australia, establishing them as leaders in the global medical cannabis market. With Germany representing an estimated 75% of the EU medical cannabis market, MediPharm Labs aims to continue shipments and innovate its offerings for this valuable market throughout 2021 and beyond.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
-
Rhea-AI Summary

MediPharm Labs Corp. (OTCQX: MEDIF) has announced the launch of its partnership with STADA Arzneimittel AG in Germany, allowing patients to access GMP-certified medical cannabis products through local pharmacies under the CannabiSTADA brand. The agreement, effective April 2021, includes the supply of eight differentiated products targeting chronic pain management. With an estimated market growth from €150m to €1.5bn by 2025 in Germany, this collaboration marks MediPharm Labs' entry into the European pharmaceutical market. STADA aims to enhance medical education and patient access to these products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
none
Rhea-AI Summary

MediPharm Labs (OTCQX: MEDIF) reported its financial results for Q4 and FY 2020, showing a sequential revenue increase of 22% to $6.1 million. Total annual revenue reached $36 million. The company achieved significant cost reductions, totaling over $3.6 million annually, while cash reserves stood at $19.9 million after repaying debts. Despite progress, the company incurred a Q4 net loss before tax of $30.9 million. They have established over 30 international agreements and received a Cannabis Drug License from Health Canada, indicating strong growth in the pharmaceutical cannabis sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
-
Rhea-AI Summary

MediPharm Labs Corp. (OTCQX: MEDIF) will release its fourth-quarter financial results on March 31, 2021. The announcement covers results for the three and twelve months ended December 31, 2020. An audio conference call and webcast are scheduled for the same day at 8:30 a.m. ET to discuss these results and the company's outlook. MediPharm Labs specializes in pharmaceutical-quality cannabis extraction and has invested in advanced technologies and facilities. The company has a fully operational Australian extraction facility and continues to expand its market reach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences earnings
-
Rhea-AI Summary

MediPharm Labs Corp. (OTCQX: MEDIF) has secured its seventh provincial distribution agreement in Quebec, enhancing its reach to over 95% of the Canadian retail market. This agreement with the Société Quebecois Du Cannabis enables the company to supply cannabis concentrate products in the province's medical and wellness sector. MediPharm's products will be available through SQDC's retail stores and online platform. Currently, it distributes in six other provinces, aiming for further expansion in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
Rhea-AI Summary

MediPharm Labs Corp. (OTCQX: MEDIF) has entered a three-year GMP white-label supply and manufacturing agreement with Cannim Australia Pty Ltd. This agreement will see the supply of specially formulated CBD and THC products under Cannim’s Lumir brand. In addition, MediPharm is launching next-generation OTC CBD products in Australia, following regulatory changes allowing low dosage CBD sales without prescriptions. The Therapeutic Goods Administration (TGA) reclassified CBD in February 2021, paving the way for enhanced market opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none

FAQ

What is the current stock price of MEDIPHARM LABS (MEDIF)?

The current stock price of MEDIPHARM LABS (MEDIF) is $0.043572 as of December 24, 2024.

What is the market cap of MEDIPHARM LABS (MEDIF)?

The market cap of MEDIPHARM LABS (MEDIF) is approximately 20.5M.

What certifications does MediPharm Labs Corp hold?

MediPharm Labs Corp holds GMP certification from ANVISA, FDA, EU, and TGA.

What products does MediPharm Labs manufacture?

MediPharm Labs manufactures authorized medical cannabis products under strict regulatory compliance, including products for the Brazilian market.

What was the significance of acquiring VIVO Cannabis?

The acquisition of VIVO Cannabis expanded MediPharm's reach to Canada, Australia, and Germany, offering a full suite of cannabis products to domestic and international medical markets.

When was MediPharm Labs Corp founded?

MediPharm Labs Corp was founded in 2015.

What is the core business of MediPharm Labs Corp?

The core business of MediPharm Labs Corp is to specialize in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and derivative products.

What is the current financial position of MediPharm Labs Corp?

MediPharm Labs Corp is in a strong financial position, with significant revenue growth and improving Adjusted EBITDA.

In which markets does MediPharm Labs operate?

MediPharm Labs operates in domestic and international medical markets, including Canada, Australia, Germany, and Brazil.

What regulatory certifications did MediPharm Labs receive in 2021?

In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada.

What is the significance of MediPharm Labs' GMP certification?

MediPharm Labs' GMP certification ensures adherence to strict manufacturing processes and facilitates access to global markets.

What is the expected growth of the Brazilian medical cannabis market?

The Brazilian medical cannabis market is expected to reach $380 million CAD in 2025.

MEDIPHARM LABS CORP

OTC:MEDIF

MEDIF Rankings

MEDIF Stock Data

20.54M
382.53M
4.45%
0.71%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Barrie